

Supplementary information




Figure S1. Comparison of relapse-free survival (RFS) between YAP1 positive and YAP1 negative patients with pure SCLC (a) and combined SCLC (b). For pure SCLC, no significant RFS was observed in YAP1 positive and YAP1 negative patients. For combined SCLC, the RFS of YAP1 positive patients was slightly shorter (median RFS: 25.2 vs 97.7 months, $P=0.366$), although the effect of YAP1 on RFS was not significant mainly due to the limited number of patients.




Figure S2. Comparison of relapse-free survival (RFS) (a) and overall survival (OS) (b) between pure SCLC (P-SCLC) and combined SCLC (C-SCLC). No significant difference for RFS ($P=0.901$) and OS ($P=0.700$) were observed.